Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Stefan, de Vogel"'
Autor:
Geir Hoff, Michael Bretthauer, Ellen Kampman, Tone Bjørge, Øivind Midttun, Åse Fredriksen, Klaus Meyer, Stein Emil Vollset, Per Magne Ueland, Jörn Schneede, Stefan de Vogel
Supplementary Tables 1 and 2 from Biomarkers Related to One-Carbon Metabolism as Potential Risk Factors for Distal Colorectal Adenomas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0afb819bfd6721868fd00eef98fd7487
https://doi.org/10.1158/1055-9965.22435471.v1
https://doi.org/10.1158/1055-9965.22435471.v1
Autor:
Geir Hoff, Michael Bretthauer, Ellen Kampman, Tone Bjørge, Øivind Midttun, Åse Fredriksen, Klaus Meyer, Stein Emil Vollset, Per Magne Ueland, Jörn Schneede, Stefan de Vogel
Background: Efficient one-carbon metabolism, which requires adequate supply of methyl group donors and B-vitamins, may protect against colorectal carcinogenesis. However, plasma folate and vitamins B2 and B12 have inconsistently been associated with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e2696e738b949d35907de87bab176eb
https://doi.org/10.1158/1055-9965.c.6514942.v1
https://doi.org/10.1158/1055-9965.c.6514942.v1
Autor:
Manon van Engeland, Matty P. Weijenberg, Piet A. van den Brandt, Royle A. Goldbohm, Adriaan P. de Bruïne, Anton F.P.M. de Goeij, Frederik J. van Schooten, Ralph W.H. Gottschalk, Kim A.D. Wouters, Stefan de Vogel
Supplementary Table 1 from Genetic Variants of Methyl Metabolizing Enzymes and Epigenetic Regulators: Associations with Promoter CpG Island Hypermethylation in Colorectal Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e2537d2a0a5133dd84fbf4e1c5fe32c
https://doi.org/10.1158/1055-9965.22435704.v1
https://doi.org/10.1158/1055-9965.22435704.v1
Autor:
Manon van Engeland, Matty P. Weijenberg, Piet A. van den Brandt, Royle A. Goldbohm, Adriaan P. de Bruïne, Anton F.P.M. de Goeij, Frederik J. van Schooten, Ralph W.H. Gottschalk, Kim A.D. Wouters, Stefan de Vogel
Aberrant DNA methylation affects carcinogenesis of colorectal cancer. Folate metabolizing enzymes may influence the bioavailability of methyl groups, whereas DNA and histone methyltransferases are involved in epigenetic regulation of gene expression.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4360b025ceaa66bab17c814a4fec9bbf
https://doi.org/10.1158/1055-9965.c.6515058
https://doi.org/10.1158/1055-9965.c.6515058
Autor:
Raoul C Reulen, Stefan de Vogel, Weide Zhong, Zhaohui Zhong, Li-Ping Xie, Zhiquan Hu, Yilan Deng, Kai Yang, Yuxiang Liang, Xing Zeng, Yong Chuan Wong, Po-Chor Tam, Marjolein Hemelt, Maurice P Zeegers
Publikováno v:
PLoS ONE, Vol 12, Iss 6, p e0178613 (2017)
Recent meta-analyses have suggested a modest protective effect of high levels of physical activity on developing both prostate and bladder cancer, but significant heterogeneity between studies included in these meta-analyses existed. To our knowledge
Externí odkaz:
https://doaj.org/article/1ad81b657d2a412d941e3360fb0babe4
Autor:
Andrea V. Margulis, Kwame Appenteng, Stefan de Vogel, Susana Perez-Gutthann, Lisa J. McQuay, Alejandro Arana, Cristina Varas-Lorenzo, Billy Franks, Maria Reynolds, Alicia Gilsenan, Christine L. Bui, Cristina Rebordosa
Publikováno v:
Pharmacoepidemiology and Drug Safety
Purpose Strategies to identify and validate acute myocardial infarction (AMI) and stroke in primary‐care electronic records may impact effect measures, but to an unknown extent. Additionally, the validity of cardiovascular risk factors that could a
Autor:
Cheryl Enger, Libby Horter, Nina Sahlertz Kristiansen, Stefan de Vogel, Kelesitse Phiri, Brandon T. Suehs, Jesper Hallas, Alejandro Arana, Marie Linder, Ingvild Odsbu, Yihua Xu, Andrea V. Margulis, Kwame Appenteng, John D. Seeger, Morten Olesen, Veena Hoffman, Susana Perez-Gutthann
Publikováno v:
Hoffman, V, Hallas, J, Linder, M, Margulis, A, Suehs, B T, Arana, A, Phiri, K, Enger, C, Horter, L, Odsbu, I, Olesen, M, Perez-Gutthann, S, Xu, Y, Kristiansen, N S, Appenteng, K, de Vogel, S, Seeger, J D & the mirabegron PMR-PASS study group 2021, ' Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder : Findings from a Non-Interventional, Multinational, Cohort Study ', Drug Safety, vol. 44, no. 8, pp. 899-915 . https://doi.org/10.1007/s40264-021-01095-7
Drug Safety
Drug Safety
Introduction During clinical trials, mirabegron, a β3-adrenoreceptor agonist, was associated with increased vital signs vs placebo in patients with overactive bladder. Objective The purpose of this study was to compare incidence rates of adverse car
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::606ed98949016a3becf28423411ba054
https://findresearcher.sdu.dk:8443/ws/files/191412893/Hoffman2021_Article_CardiovascularRiskInUsersOfMir.pdf
https://findresearcher.sdu.dk:8443/ws/files/191412893/Hoffman2021_Article_CardiovascularRiskInUsersOfMir.pdf
Autor:
John D. Seeger, Marie Linder, Veena Hoffman, Alejandro Arana, Shahram Bahmanyar, Susana Perez-Gutthann, Jesper Hallas, Libby Horter, Brandon T. Suehs, Stefan de Vogel, Kelesitse Phiri, Nina Sahlertz Kristiansen, Andrea V. Margulis, Ingvild Odsbu, Kwame Appenteng, Cheryl Enger, Morten Olesen
Publikováno v:
Phiri, K, Hallas, J, Linder, M, Margulis, A, Suehs, B, Arana, A, Bahmanyar, S, Hoffman, V, Enger, C, Horter, L, Odsbu, I, Olesen, M, Perez-Gutthann, S, Kristiansen, N S, Appenteng, K, de Vogel, S & Seeger, J 2021, ' A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder ', Current Medical Research and Opinion, vol. 37, no. 5, pp. 867-877 . https://doi.org/10.1080/03007995.2021.1891035
the Mirabegron PMR-PASS study group 2021, ' A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder ', Current Medical Research and Opinion . https://doi.org/10.1080/03007995.2021.1891035
the Mirabegron PMR-PASS study group 2021, ' A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder ', Current Medical Research and Opinion . https://doi.org/10.1080/03007995.2021.1891035
Objective: This post-authorization safety study (EU PAS Register Number: EUPAS16088) was designedto compare the incidence of cancer outcomes in patients treated with mirabegron versus antimuscarinicmedications.Methods: Cohorts of mirabegron initiator
Autor:
John D. Seeger, Stefan de Vogel, Andrea V. Margulis, Susana Perez Gutthann, Jesper Hallas, Kwame Appenteng, Brandon T. Suehs, Alejandro Arana, Morten S. Olesen, Nina Sahlertz Kristiansen, Cheryl Enger, Libby Horter, Veena Hoffman, Yihua Xu, Ingvild Odsbu, Marie Linder
Publikováno v:
Circulation. 142
Introduction: During clinical trials, mirabegron, a β3-adrenoreceptor agonist, was associated with increased heart rate and systolic/diastolic blood pressure vs placebo in patients with overactive bladder (OAB). We studied the association between mi
Autor:
Stefan de Vogel, Irene D. Bezemer, Daniel Dedman, Fabian Hoti, Noah Jamie Robinson, Daniel Prieto-Alhambra, Fernie J. A. Penning-van Beest, Helen P Booth, Minna Vehkala, Kwame Appenteng, Edith M. Heintjes, Ying He, Elisabeth Smits
Publikováno v:
Clinical Epidemiology
Edith M Heintjes,1 Irene D Bezemer,1 Daniel Prieto-Alhambra,2,3 Elisabeth Smits,1 Helen P Booth,4 Daniel Dedman,4 Ying He,3 Fabian Hoti,5 Minna Vehkala,5 Stefan de Vogel,6 Noah Jamie Robinson,6 Kwame Appenteng,7 Fernie JA Penning-van Beest1 1PHARMO I